Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations

被引：0

作者：

Garmezy, B. ^{[1
]}

Borad, M. ^{[2
]}

Lin, C. C. ^{[3
]}

Chen, L. T. ^{[4
]}

Perez, C. A. ^{[5
]}

Kato, S. ^{[6
]}

Tam, B. ^{[7
]}

Severson, P. ^{[8
]}

Quah, C. S. ^{[9
]}

Harding, J. J. ^{[10
]}

机构：

[1] Sarah Cannon Res Inst, Res, Nashville, TN USA

[2] Mayo Clin, Ctr Canc, Oncol Dept, Scottsdale, AZ USA

[3] NTUH Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[4] Kaohsiung Med Univ, Chung Ho Mem Hosp, Hematol Dept, Kaohsiung, Taiwan

[5] Florida Canc Specialists, Med Oncol, Ft Myers, FL USA

[6] Univ Calif San Diego UCSD, Med Oncol, La Jolla, CA USA

[7] Kinnate Biopharma, Clin Sci, San Diego, CA USA

[8] Kinnate Biopharma Inc, Translat Med, San Diego, CA USA

[9] Kinnate Biopharma, Clin Dev, San Diego, CA USA

[10] Mem Sloan Kettering Evelyn H Lauder Breast Ctr, Med, New York, NY USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1423

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

130P

引用

页码：S231 / S232

页数：2

共 46 条

[21] First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors
Goyal, L.
Subbiah, V.
Mahipal, A.
Kamath, S.
Mody, K.
Borad, M.
El-Khoueiry, A.
Sahai, V.
Kim, R.
Kelley, R.
Schmidt-Kittler, O.
Shen, J.
Jen, K.
Deary, A.
Padval, M.
Sherwin, C.
Wolf, B.
Schram, A.
ANNALS OF ONCOLOGY, 2021, 32 : S120 - S120
[22] A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301).
Hansen, Aaron Richard
Zhang, Alison Yan
Boni, Valentina
Mantia, Charlene
Yu, Evan Y.
Weickhardt, Andrew James
Robert, Marie
Gupta, Shilpa
Morales-Barrera, Rafael
Hoimes, Christopher J.
Berlin, Jordan
Iyer, Gopa
Millward, Michael
Lihou, Christine Francis
Loriot, Yohan
Pouessel, Damien
Mittal, Kriti
Hill, Andrew Graham
Racca, Fabricio
Tran, Ben
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS904 - TPS904
[23] First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.
Schram, Alison M.
Kamath, Suneel Deepak
El-Khoueiry, Anthony B.
Borad, Mitesh J.
Mody, Kabir
Mahipal, Amit
Goyal, Lipika
Sahai, Vaibhav
Schmidt-Kittler, Oleg
Shen, Jinshan
Jen, Kai Yu
Deary, Alicia
Sherwin, Cori Ann
Padval, Mahesh
Wolf, Beni B.
Subbiah, Vivek
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[24] Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.
Cleary, James M.
Iyer, Gopa
Oh, Do-Youn
Mellinghoff, Ingo K.
Goyal, Lipika
Ng, Matthew C. H.
Meric-Bernstam, Funda
Matos, Ignacio
Chao, Tsu-Yi
Sarkouh, Rafik Ait
Cretegny, Kira
Nicolas-Metral, Valerie
Pokorska-Bocci, Anna
Vaslin, Anne
Zanna, Claudio
Zubel, Angela
Tabernero, Josep
Flaherty, Keith
Hyman, David Michael
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[25] A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1.
Iyer, Gopa
Ebi, Hiromichi
Cook, Natalie
Gao, Xin
Kitano, Shigehisa
Matsubara, Nobuaki
Reimers, Melissa A.
Siefker-Radtke, Arlene O.
Kim, Miso
Galsky, Matthew D.
Robbrecht, Debbie G. J.
Guo, Jun
Eigl, Bernhard J.
Schaverien, Clare
Butts, Brent
Yuen, Eunice
Szymczak, Sylwia
Zhao, Xiang
Widau, Ryan C.
Drakaki, Alexandra
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
[26] Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.
Javle, Milind M.
Roychowdhury, Sameek
Kelley, Robin Kate
Sadeghi, Saeed
Macarulla, Teresa
Waldschmidt, Dirk Thomas
Goyal, Lipika
Borbath, Ivan
El-Khoueiry, Anthony B.
Yong, Wei-Peng
Philip, Philip Agop
Bitzer, Michael
Tanasanvimon, Suebpong
Li Ai
Pande, Amit
Shepherd, Stacie Peacock
Moran, Susan
Abou-Alfa, Ghassan K.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[27] TYRA-300, an oral, FGFR3-selective inhibitor: Preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations
Loriot, Y.
Zhang, A.
Hansen, A.
Mantia, C.
Boni, V.
Weickhardt, A.
Yu, E. Y.
Robert, M.
Iyer, G.
Murtha, A.
Owens, S.
Suttle, B.
Vandekerkhove, G.
Wyatt, A.
Gammon, G.
Burn, T.
Tran, B.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S32 - S33
[28] Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors
Bahleda, R.
Meric-Bernstam, F.
Goyal, L.
Tran, B.
He, Y.
Yamamiya, I
Benhadji, K. A.
Matos, I
Arkenau, H-T
ANNALS OF ONCOLOGY, 2020, 31 (10) : 1405 - 1412
[29] Phase I study of the irreversible FGFR inhibitor futibatinib in Japanese patients with advanced solid tumors: Updated dose expansion results and activity in gastric cancer
Kuboki, Y.
Shitara, K.
Morizane, C.
Kojima, T.
Yoh, K.
Sakai, D.
Tahara, M.
Hirai, H.
Kurokawa, Y.
Kato, T.
Doi, T.
ANNALS OF ONCOLOGY, 2021, 32 : S1047 - S1048
[30] Ongoing phase 2 study of erdafitinib (JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (M/UR UC) and FGFR gene alterations
Siefker-Radtke, A. O.
Mellado, B.
Decaestecker, K.
Burke, J. M.
O'Hagan, A.
Avadhani, A.
Zhong, B.
Santiago-Walker, A.
De Porre, P.
Brookman-May, S.
Garcia-Donas, J.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →